Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
-
- Ludovico Abenavoli
- Department of Health Sciences, University “Magna Graecia”, Viale Europa-Germaneto, 8810 Catanzaro, Italy
-
- Tetyana Falalyeyeva
- School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64/13, 01601 Kiev, Ukraine
-
- Luigi Boccuto
- Greenwood Genetic Center, Greenwood, SC 29646, USA
-
- Olena Tsyryuk
- School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64/13, 01601 Kiev, Ukraine
-
- Nazarii Kobyliak
- Department of Endocrinology, Bogomolets National Medical University, Pushkinska 22a, 01610 Kiev, Ukraine
説明
<jats:p>The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.</jats:p>
収録刊行物
-
- Pharmaceuticals
-
Pharmaceuticals 11 (4), 104-, 2018-10-11
MDPI AG
